Blog

Wednesday, March 18: Today in Gold and Silver

NEW YORK (TheStreet) — The gold price traded in a pretty tight range through all of Far East trading on their Tuesday—but once London opened, the price developed its usual negative bias—and around 8:45 a.m. EDT, the HFT boyz and their algorithms stepped in—and the low tick came about 9:20 a.m.—which was another new low for this move down.  From there it blasted higher into the London p.m. gold “fix”—and

Tuesday, March 17: Today in Gold and Silver

NEW YORK (TheStreet) — Monday’s trading session in gold turned out pretty much as expected, with the high tick coming just before the London open—and it was all down hill into the on-the-dot 11:00 a.m. EDT low, which was probably the close of gold trading in London as well.  From there it rallied unsteadily into the close of electronic trading.  This was same trading pattern as we’ve had during the

Saturday, March 14: Today in Gold and Silver

NEW YORK (TheStreet) — As has been the case for three days in a row, the smallish rally in gold in Far East trading met the usual not-for-profit sellers an hour or so before the London open.  The low tick came shortly after 11:00 a.m. EDT in New York.  The gold price rallied quietly from there, before tacking on another quick five bucks in the last hour of trading in

March Madness to the Masters: The Best Time to Sell a House

Filed under: Selling Alamy By Catherine Sherman You've heard it before: List your home early in the year. That way, you'll be ready to close the deal when home sales peak in June. But what exactly does "early in the year" mean? Based on an analysis of supply, demand and sellers' outcomes in the book "Zillow Talk: The New Rules of Real Estate," co-authors Spencer Rascoff and Stan Humphries have

Campaign hopes for Tasmanian tobacco-free generation law

Campaigners for a proposed law to ban tobacco sales to anyone born after 2000 said Thursday they were hopeful the bill will be adopted by an Australian state’s parliament next week. Under the bill, the island of Tasmania would lift the age at which people can legally buy cigarettes — currently 18 — a year at a time to achieve a “tobacco-free generation”. “Tuesday is the vote in the legislative

Exclusive: Despite Hillary Clinton promise, charity did not disclose donors

By Jonathan Allen NEW YORK (Reuters) – In 2008, Hillary Clinton promised Barack Obama, the president-elect, there would be no mystery about who was giving money to her family’s globe-circling charities. She made a pledge to publish all the donors on an annual basis to ease concerns that as secretary of state she could be vulnerable to accusations of foreign influence. At the outset, the Clinton Foundation did indeed publish

FDA panel backs Glaxo asthma drug for adults, not adolescents

(Reuters) – GlaxoSmithKline Plc’s drug to treat chronic breathing problems is safe and effective enough to be approved in adults with asthma, but not adolescents, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. The panel voted 16-4 that the product, Breo Ellipta, should be approved for once daily treatment of asthma in adults 18 years and older. The FDA is not obliged to follow the

Sixth Oregon college student stricken by meningococcal disease

By Shelby Sebens PORTLAND, Ore. (Reuters) – A sixth University of Oregon student has contracted the potentially deadly meningococcal disease amid an outbreak that erupted in January, and more cases could emerge, public health officials said on Thursday. Health officials said a 20-year-old college sophomore who lives off campus has been confirmed as having contracted meningococcemia, a bacterial precursor to meningitis that can also lead to damaging blood infections. The

U.S. judge rejects Amgen bid to block 'biosimilar' Neupogen

By Ransdell Pierson NEW YORK (Reuters) – A U.S. judge on Thursday denied Amgen Inc’s bid to block the sale of Novartis AG’s recently approved “biosimilar” form of Neupogen, Amgen’s blockbuster drug used to prevent infections in cancer patients. The drug, Zarxio, contains the same active ingredient as Amgen’s $1.2 billion-a-year Neupogen, and once launched, would become the first biosimilar in the United States.